Erratum for vol. 100, p. 1566

Regarding the article by Wanless et al entitled “Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia,” which appeared in the September 1, 2002, issue of Blood (Volume 100:1566-1569), please note the following additional statement by the authors:

R.G. (Renzo Galanello), A.P., R.G. (Rita Gamberini), and A.C. have received support from Apotex for other research studies and have received reimbursement for travel expenses related to meetings of investigators and scientific meetings at which results were presented. E.S. served on the Data and Safety Monitoring Committee for other Apotex-sponsored trials and received reimbursement for travel expenses related to meetings of this committee. The present study received no support from Apotex, and none of the authors involved in the interpretation of the liver biopsies or the analysis of the data received previous support from Apotex.

Editor's note: This financial disclosure was provided at the request of the journal and was not information originally withheld.